Stephen Collins

Dr. Collins has led or had senior leadership positions in multiple pharmaceutical and biotech companies in a wide range of therapeutics areas, resulting in over a dozen approved drugs, devices and drug-device combinations, and multiple company acquisitions. Currently, he is Executive Chairman of Vetana Animal Health, Inc. a biologics based, anti-inflammatory-focused company in clinical studies of a novel platform for improving the lives of dogs, cats, and horses. Most recently he was Chief Executive Officer of Biscayne Neurotherapeutics, an early clinical-stage company sold to Supernus Pharmaceuticals. Earlier, he was Chief Scientific Officer and Chief Medical Officer of Ovation Pharmaceuticals, an oncology and CNS-focused company acquired by Lundbeck A/S. Prior to Ovation, Steve served as a Global Director and member of the Global In-Licensing Advisory Team at Johnson & Johnson and before that worked in Abbott Laboratories’ Pharmaceutical and Hospital Products Divisions. He has served on the boards of Engage Therapeutics, which was sold to UCB Pharmaceuticals, and Spinifex Pharmaceuticals, acquired by Novartis. Prior to industry, Dr. Collins served on the faculties of medicine at Case Western Reserve University and the University of California-San Francisco. He earned his MD and PhD at Case Western Reserve University after completing undergraduate studies in Physics at the University of California, Berkeley.